Want to travel while on GLP-1 medications
Like resM, it lacks major published clinical trial data specific to the product formulation
For unpublished trials, we searched trial registries (such as clinicaltrials.gov) and preprint websites and obtained results of an included trial in this review through a combination of both [16]
Novel medications might facilitate the maintenance of weight loss after discontinuation, but additional studies are required to evaluate their long-term efficacy
The combination of a levonorgestrel-releasing intrauterine device (LNG-IUD), metformin, and liraglutide has been shown to safely and effectively improve endometrial hyperplasia in obese patients, as well as promote the regression of early-stage endometrial cancer [41]

Resources: GLP-1 Agonists Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes Safety of Semaglutide Once-Weekly Semaglutide in Adults with Overweight or Obesity Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity Medication-Induced Gastroparesis: A Case Report Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASSCVOT design and baseline characteristics Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trial Tirzepatide prevents neurodegeneration through multiple molecular pathways TripleHormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial Biology of Incretins: GLP-1 and GIP GIP and GLP1, the two incretin hormones: Similarities and differences GLP-1, GIP and glucagon receptor poly-agonists: A new era in obesity pharmacotherapy
